TICKERNERD
Menu
CTMXCTMXHealthcare · Biotechnology

CTMX Stock Forecast: CytomX Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$3.36
+0.30% on the day

The 8 Wall Street analysts covering CytomX Therapeutics, Inc. hold a median 12-month price target of $12 — +257.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 51 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$732.1M
Ticker Nerd rank
51 / 100
Median analyst target
$12
Analysts covering
8
Total return, dividends reinvested
1W
−2.9%
1M
−8.2%
YTD
−21.1%
1Y
+90.9%
From 52W high
−50.2%
From 52W low
+90.9%
$1.76
$6.75
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTMX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores CytomX Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
51 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
72
Quality
71
Value
71
Momentum
68
Size
49
Issuance
37
Accruals
35
Volatility
26
Growth
17

Revisions (72): Analysts have, on balance, been raising their forecasts.

Growth (17): Sales and profits are flat, shrinking, or growing more slowly than they were.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTMX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTMX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26CTMXHigh $16Median $12Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
8 Buy0 Hold0 Sell
Low $6Median $12High $16

The green dot is the last close — the median target sits +257.1% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
13 Aug 2026JP MorganMaintainsOverweight$12 → $11
10 Aug 2026GuggenheimMaintainsBuy$15 → $14
11 May 2026HC Wainwright & Co.MaintainsBuy$17 → $11
11 May 2026HC Wainwright & Co.MaintainsBuy—
23 Mar 2026Piper SandlerMaintainsOverweight—
19 Mar 2026BarclaysMaintainsOverweight—
18 Mar 2026GuggenheimMaintainsBuy—
18 Mar 2026JefferiesMaintainsBuy—
17 Mar 2026WedbushMaintainsOutperform—
16 Mar 2026HC Wainwright & Co.MaintainsBuy—
16 Mar 2026JP MorganUpgradeOverweight—
9 Mar 2026GuggenheimReiteratesBuy—
4 Feb 2026BarclaysMaintainsOverweight—
4 Feb 2026Cantor FitzgeraldMaintainsOverweight—
20 Jan 2026BarclaysMaintainsOverweight—
20 Jan 2026GuggenheimInitiatesBuy—
20 Jan 2026Piper SandlerMaintainsOverweight—
11 Nov 2025HC Wainwright & Co.MaintainsBuy—
21 Oct 2025BarclaysMaintainsOverweight—
22 Sept 2025Cantor FitzgeraldInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTMX appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CTMX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
4
Fundamentals

CytomX Therapeutics, Inc. (CTMX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
15.9×

Cheaper than 46% of US stocks

Price / sales
40.0×

Cheaper than 6% of US stocks

Price / book
2.4×

Cheaper than 41% of US stocks

EV / EBITDA
−4.7×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
−92.4%

Higher than 2% of US stocks

Earnings growth (YoY)
−92.4%

Higher than 3% of US stocks

Gross margin
—
Operating margin
−1677.1%

Higher than 5% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−37.8%

Higher than 25% of US stocks

Return on assets
−19.6%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CTMX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTMXCytomX Therapeutics, Inc.$732.1M
51
BBOTBridgebio Oncology Therapeutics, Inc.$717.5M
12
DRUGBright Minds Biosciences, Inc.$743.9M
44
STTKShattuck Labs, Inc.$744.7M
76
GYREGyre Therapeutics, Inc.$744.7M
39
PHATPhathom Pharmaceuticals, Inc.$750.1M
80
RGNXREGENXBIO, Inc.$703.1M
56

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own CytomX Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTMX news & analysis

CytomX Therapeutics: Promising Varseta-M With Comfortable Runway

Seeking Alpha · 12 Aug 2026positive

A Seeking Alpha article discusses CytomX Therapeutics' PROBODY platform and its lead asset Varseta-M, noting early colorectal cancer activity but stressing the need for larger and more mature datasets. It highlights upcoming data catalysts, including a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts through the first half of 2027.

Why it matters — A CTMX watcher would care because the article outlines several near-term pipeline catalysts from Varseta-M and the PROBODY platform that could shape the company's outlook.

CytomX Therapeutics, Inc. (CTMX) Q2 2026 Earnings Call Transcript

Seeking Alpha · 7 Aug 2026neutral

CytomX Therapeutics held its Q2 2026 earnings call, and Seeking Alpha published a transcript of the event. The excerpt contains only the headline and attribution identifying the transcript's availability.

Why it matters — The Q2 2026 earnings call transcript provides CTMX watchers with direct insight into the company's latest quarterly results and management commentary.

CytomX Therapeutics Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

CytomX Therapeutics reported that its second-quarter focus centered on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers.

Why it matters — The update highlights management's continued commitment to advancing Varseta-M, the company's key pipeline asset, and its expansion into new indications.

CytomX Therapeutics (CTMX) Reports Q2 Loss, Lags Revenue Estimates

Zacks Investment Research · 7 Aug 2026neutral

CytomX Therapeutics reported a Q2 loss of $0.09 per share, narrower than the Zacks Consensus Estimate of a $0.11 loss, though it compared unfavorably with break-even earnings per share a year ago. Revenue came in below consensus estimates for the quarter.

Why it matters — The results offer CTMX watchers an update on the company's quarterly financial performance, including a tighter-than-expected loss offset by a revenue miss versus estimates.

CytomX Therapeutics Announces Q2 2026 Financial Results and Provides Business Update

GlobeNewsWire · 6 Aug 2026neutral

CytomX Therapeutics announced its Q2 2026 financial results and provided a business update. The company expects Phase 1 monotherapy data for Varseta-M in advanced colorectal cancer by end of 2026, with a registrational study planned to begin in the first half of 2027, and noted that the Phase 1 combination study with bevacizumab in 3L+ metastatic colorectal cancer is ongoing.

Why it matters — The Varseta-M program is a key pipeline asset for CytomX, and the upcoming Phase 1 data readout and planned registrational study represent important upcoming milestones that CTMX watchers will be tracking.

FAQ

Frequently asked questions about CTMX stock

What is the CTMX stock price forecast for 2026-2027?

The 8 Wall Street analysts covering CytomX Therapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $6 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTMX stock a buy right now?

Of the 8 analysts covering CytomX Therapeutics, Inc., 8 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks CytomX Therapeutics, Inc. 51 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTMX?

As at 15 Aug 2026, CytomX Therapeutics, Inc. ranks 51 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (72 of 100).

Will CTMX stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +257.1% from the last close, and Ticker Nerd's factor model ranks CytomX Therapeutics, Inc. 51 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTMX stock forecast for 2030?

No analyst covering CytomX Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTMX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $16 over the next 12 months.

How has CTMX stock performed over the past year?

CytomX Therapeutics, Inc. returned +90.9% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does CytomX Therapeutics, Inc. do?

CytomX Therapeutics Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing novel conditionally activated biologics designed to be localized to the tumor microenvironment.

What is the latest news on CTMX?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "CytomX Therapeutics: Promising Varseta-M With Comfortable Runway". A Seeking Alpha article discusses CytomX Therapeutics' PROBODY platform and its lead asset Varseta-M, noting early colorectal cancer activity but stressing the need for larger and more mature datasets. It highlights upcoming data catalysts, including a Varseta-M monotherapy update, combination-study data, and new gastrointestinal cohorts through the first half of 2027.

Company

About CytomX Therapeutics, Inc.

CytomX Therapeutics Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. The company's proprietary PROBODY® therapeutic platform creates masked molecules that remain inactive in circulation and normal tissues but become activated within tumors, aiming to enhance anti-cancer efficacy while minimizing effects on healthy tissues. CytomX's clinical pipeline includes varsetatug masetecan, a masked antibody-drug conjugate targeting EpCAM for colorectal cancer, and CX-801, an interferon alpha-2b cytokine for melanoma and other oncology indications. The company also develops T-cell engagers and other immune-modulating therapies across multiple treatment modalities. CytomX maintains strategic research collaborations with major biopharmaceutical partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, focusing on advancing its platform technology across various cancer types. Based in South San Francisco, California, CytomX operates as a clinical-stage developer with a focus on expanding the therapeutic window for targets previously considered difficult to drug due to expression on normal tissues.

CEO Dr. Sean A. McCarthy DPHIL · 69 employees · United States · https://www.cytomx.com